Allorion Therapeutics is a biotechnology startup that specializes in the development of next-generation targeted drugs for cancer and autoimmune diseases. The company operates in the pharmaceutical market, specifically in the oncology and autoimmune sectors. The team at Allorion is composed of experts in cancer biology and drug development, which gives them a competitive edge in their field.

The company's business model revolves around the development of novel small molecule drugs. They do this by selecting well-validated targets with clear clinical development routes and discovering their modulators with distinct mechanisms of action. Their innovative data and screening platforms play a crucial role in this process, as they allow for the identification of novel targets and chemicals.

Allorion also constructs chemical libraries, prioritizing allosteric and covalent modulators, and optimizes these libraries with the help of artificial intelligence (AI). This approach allows them to develop mutant selective and isoform-specific drugs in non-conventional ways, improving efficacy and preventing resistance.

The company's revenue is likely generated through the licensing and sale of their developed drugs to larger pharmaceutical companies or healthcare providers. They may also receive funding from research grants or investors interested in the biotech sector.

Allorion Therapeutics is based in Boston, with both office and lab facilities located in Natick, Massachusetts.

Keywords: Biotechnology, Cancer, Autoimmune Diseases, Drug Development, Small Molecule Drugs, Targeted Therapies, Precision Medicine, Artificial Intelligence, Chemical Libraries, Pharmaceutical Market.